Insider Selling: Alumis (NASDAQ:ALMS) CFO Sells $86,546.34 in Stock

Alumis Inc. (NASDAQ:ALMS) CFO John Schroer sold 3,282 shares of Alumis stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $86,546.34. Following the completion of the sale, the chief financial officer owned 24,718 shares of the company’s stock, valued at $651,813.66. The trade was a 11.72% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alumis Price Performance

Shares of Alumis stock opened at $27.60 on Friday. The stock has a market cap of $3.52 billion, a price-to-earnings ratio of -13.94 and a beta of -0.69. The firm’s 50-day moving average is $25.62 and its two-hundred day moving average is $25.26. Alumis Inc. has a 1 year low of $3.76 and a 1 year high of $31.35.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. On average, equities analysts expect that Alumis Inc. will post -2.87 earnings per share for the current year.

Hedge Funds Weigh In On Alumis

Several hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in Alumis in the 2nd quarter worth approximately $231,259,000. Samsara Biocapital LLC increased its stake in Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock valued at $56,188,000 after purchasing an additional 955,614 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Alumis by 18.4% in the third quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after buying an additional 625,404 shares during the last quarter. Cormorant Asset Management LP raised its holdings in shares of Alumis by 69.3% in the fourth quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock worth $35,483,000 after buying an additional 1,488,200 shares during the last quarter. Finally, Octagon Capital Advisors LP lifted its stake in shares of Alumis by 11.9% during the first quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock worth $62,360,000 after buying an additional 300,000 shares during the period.

Wall Street Analysts Forecast Growth

ALMS has been the topic of several recent research reports. Wells Fargo & Company increased their target price on Alumis from $49.00 to $51.00 and gave the company an “overweight” rating in a research report on Friday, May 15th. Citigroup reissued a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. HC Wainwright restated a “neutral” rating and set a $25.00 price objective on shares of Alumis in a research note on Monday, August 3rd. Guggenheim raised their price objective on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $39.00 target price on shares of Alumis in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Alumis has an average rating of “Moderate Buy” and a consensus target price of $40.30.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.